Effexor Follow-On Will Launch One Year Before XR Patent Expires, Wyeth Says
Executive Summary
Wyeth expects to have about one year to switch Effexor XR patients to its follow-on serotonin and norepinephrine reuptake inhibitor DVS-233 before venlafaxine XR loses market exclusivity in 2008
You may also be interested in...
WHI Premarin Data Will Not Affect Bazedoxifene Phase III Studies, Wyeth Says
The Women's Health Initiative hormone therapy safety findings will not affect the regulatory pathway for Wyeth's Phase III estrogen/SERM combination, VP-Investor Relations Justin Victoria said
Premarin WHI Results May Mean Additional Labeling Changes, FDA Says
FDA may request additional changes to the labeling of hormone replacement therapies based on the findings from the terminated Premarin arm of the Women's Health Initiative
Prempro Cancer Risk Addressed In 550,000 Physician Letters, Label Review
Wyeth is sending letters to approximately 550,000 physicians as part of a Prempro risk management program to address risks associated with use of the hormone combination for cardiovascular disease and osteoporosis prevention